title: Simulating fasted human intestinal fluids: understanding the roles of lecithin and bile acids.
abstract: The purpose of this work is to evaluate the roles of lecithin and bile salts in a new generation of fasted simulated small intestinal fluid (FaSSIF-II), thus enhancing the closer mimic of simulated fluids to the real human intestinal fluids (HIF) in drug discovery and drug product development. To assess the effects of lecithin in FaSSIF-II, solubility studies were conducted at 37 °C using four media including first generation simulated intestinal fluid (FaSSIF-I), FaSSIF-II, phosphate pH 6.5 buffer, and HIF. A total of 24 model compounds representing a wide range of biopharmaceutic properties were included. The drug solubility values measured in the FaSSIF-II were compared with those in FaSSIF-I, pH 6.5 buffer and HIF. To assess the effects of bile acids, solubility was measured for 4 compounds in the FaSSIF-I containing five different bile acids of various concentrations. The lecithin concentration in the FaSSIF-II is lowered from 0.75 mM to 0.2 mM. The results suggested that the FaSSIF-II is a better medium to reflect HIF, compared with pH 6.5 phosphate buffer and FaSSIF-I. Solubility of neutral compounds including atovaquone, carbamazepine, cyclosporine, danazol, diethylstilbestrol, felodipine, griseofulvin and probucol in FaSSIF-II showed improvement in predicting the in vivo solubility. The relative standard deviation (SD) of solubility measurement in FaSSIF-II is comparable with FaSSIF-I. For the acidic and basic tested compounds, the FaSSIF-II performs similarly to the FaSSIF-I. Experimental results showed that the level of bile salts typically is less than 5 mM under fasted state. Among the five studied bile acids, the conjugation (glycine or taurine) has no impact on the drug solubilization, while there may be a minimal effect of the degree of hydroxylation of the steroid ring system on solubilization. The lecithin concentration of 0.2 mM in FaSSIF-II has been demonstrated to closely represent HIF, for both neutral and ionizable compounds. In the composition of simulated intestinal fluids, the structure of bile acids has minimal effect, providing the flexibility of choosing one bile salt to represent complex in vivo bile acids.
authors.affiliation: Pharmaceutical Development, AstraZeneca R&D, Mölndal, Sweden.
authors.forename: Erik
authors.initials: E
authors.lastname: Söderlind
authors.forename: Eva
authors.initials: E
authors.lastname: Karlsson
authors.forename: Anders
authors.initials: A
authors.lastname: Carlsson
authors.forename: Rui
authors.initials: R
authors.lastname: Kong
authors.forename: Anna
authors.initials: A
authors.lastname: Lenz
authors.forename: Sara
authors.initials: S
authors.lastname: Lindborg
authors.forename: Jennifer J
authors.initials: JJ
authors.lastname: Sheng
mesh_terms: D001647:Bile Acids and Salts / Q000378:metabolism*; D001826:Body Fluids / Q000378:metabolism; D002626:Chemistry, Pharmaceutical; D055808:Drug Discovery; D005215:Fasting / Q000378:metabolism*; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007408:Intestinal Absorption; D007421:Intestine, Small / Q000378:metabolism*; D054709:Lecithins / Q000378:metabolism*; D008954:Models, Biological; D010599:Pharmacokinetics; D012995:Solubility; D013810:Therapeutic Equivalency
chemical_list: D001647:Bile Acids and Salts; D054709:Lecithins